Samsara Therapeutics
Susan Perlman MD, PhD is Clinical Professor in the Department of Neurology at the David Geffen School of Medicine at UCLA and Director of the Ataxia and Neurogenetics Clinical Trials Programs. Prof Perlman is a well-known neuro-geneticist and clinical pioneer in ataxia who sits on the Medical-Research Advisory Board of the National Ataxia Foundation. Perlman received her BS in Biochemistry from Cornell University and MD from SUNY, Stony Brook. She did her Residency in Neurology at UCLA, followed by a Muscular Dystrophy Association Fellowship in Neurology also at UCLA. In 2008, she received the Sherman M Mellinkoff Faculty Award, considered the highest faculty distinction at the David Geffen School of Medicine.
This person is not in the org chart
This person is not in any offices
Samsara Therapeutics
Samsara Therapeutics, Inc. is a biopharmaceutical company aiming to discover the first-in-class therapeutics that treat rare genetic and neurodegenerative diseases and extend a healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy.